Advertisement


David S. Hong, MD, on New Findings on Tisotumab Vedotin-tftv in Patients With Head and Neck Squamous Cell Carcinoma

2022 Multidisciplinary Head and Neck Cancers Symposium

Advertisement

David S. Hong, MD, of The University of Texas MD Anderson Cancer Center, discusses results from a phase II cohort, which suggest favorable antitumor activity with tisotumab vedotin-tftv in patients with head and neck squamous cell carcinoma that has progressed after treatment with a platinum-containing regimen. Additional research is warranted, says Dr. Hong, in the second-line setting as well as in treatment-naive patients in combinations with pembrolizumab and carboplatin.



Related Videos

Head and Neck Cancer

Peter Zeng, MD/PhD Candidate: Immune Cell Signature Predicts Survival in HPV-Associated Head and Neck Cancer

Peter Zeng, MD/PhD Candidate, at Ontario’s Western University, discusses a three-gene prognostic classifier tool, known as UWO3, which was validated in six external cohorts and shown to identify patients with human papillomavirus–related head and neck cancer that is likely to recur following aggressive radiation de-escalation.

Head and Neck Cancer

Elizabeth D. Cash, PhD, on Addressing the Psychological Aspects of Head and Neck Cancer

Elizabeth D. Cash, PhD, of the University of Louisville, discusses depression among patients with head and neck cancer, the impact it can have on prognosis, and the importance of helping patients cope through screening for depressive symptoms and treatment with collaborative care models.

Head and Neck Cancer

Glenn J. Hanna, MD, on Oropharyngeal Squamous Cell Carcinoma: Detecting Occult Recurrence

Glenn J. Hanna, MD, of Dana-Farber Cancer Institute and Harvard Medical School, discusses findings that show human papillomavirus circulating tumor DNA (HPV ctDNA) may be useful as part of surveillance monitoring of patients with oropharyngeal squamous cell carcinoma. Dr. Hanna reports that 93% of patients who had no clinical evidence of disease developed a positive HPV ctDNA test during surveillance follow-up and subsequently had confirmed disease recurrence.

Thyroid Cancer

Sue S. Yom, MD, PhD, on Thyroid Cancer: Expert Perspective on the State of the Field

Sue S. Yom, MD, PhD, of the University of California, San Francisco, discusses some of the latest developments in thyroid cancer, including the mutational landscape, therapies for high-risk and anaplastic diseases, and multimodalities for aggressive differentiated thyroid cancers.

Head and Neck Cancer

Phillip Pifer, MD, PhD, on Head and Neck Squamous Cell Carcinoma: New Data on Focal Adhesion Kinase

Phillip Pifer, MD, PhD, of the UPMC Hillman Cancer Center, discusses findings that suggest focal adhesion kinase is a potentially important target for therapeutic sensitization in patients with mutant TP53 HPV-negative head and neck squamous cell carcinoma.

Advertisement

Advertisement



Advertisement